Milestone Pharmaceuticals at Needham Virtual Healthcare Conference

MONTREAL and CHARLOTTE, N.C., April 07, 2026 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development of commercialization of innovative cardiovascular medicines, today announced that management will present at the 25th Annual Needham Virtual Healthcare Conference to take place April 13 - 16, 2026.

Milestone Pharmaceuticals is preparing to showcase its progress and developments during the 25th Annual Needham Virtual Healthcare Conference, highlighting a noteworthy stage in their journey. The conference, which allows companies to showcase their innovations to investors and stakeholders, serves as a vital platform for Milestone Pharmaceuticals to discuss its strategic vision and pipeline.

Milestone Pharmaceuticals is a biopharmaceutical company specializing in developing innovative therapies for the treatment of cardiovascular diseases. Their flagship product, etripamil, is under investigation for its safety and efficacy in various cardiovascular indications. The upcoming presentation aims to provide an update on the status of etripamil, including clinical trial results and future milestones.

The Needham Conference is a significant event for investors seeking insights into the healthcare sector, with a focus on breakthrough therapies and innovations. Milestone’s participation is an opportunity to engage with both potential and existing investors, discussing the company's strategic direction and forthcoming milestones that could shape its future.

Moreover, the conference provides access to a diverse array of healthcare companies, allowing for networking opportunities and discussions on the latest trends in the industry. Milestone Pharmaceuticals stands out among its peers with a compelling strategy centered around innovation in treatment options for patients affected by cardiovascular issues.

In essence, Milestone Pharmaceuticals' presentation at the Needham Virtual Healthcare Conference signals its commitment to advancing healthcare solutions while fostering relationships with investors. By sharing insights into their clinical studies and operational strategies, the company aims to boost stakeholder confidence and underscore its potential in revolutionizing cardiovascular treatment.